Goodwin’s Alexandra Valenti discusses the future of the Biologics Price Competition and Innovation Act (BPCIA) in light of challenges to the Affordable Care Act with The Center for Biosimilars. Watch the video here.
Related Content
- InsightNovember 8, 2024
Life Sciences M&A Trends for 2023 and 2024 (Through End of Q3) in Greater China
- Big Molecule WatchNovember 7, 2024
FDA Accepts BLA for Shanghai Henlius Biotech’s and Organon’s HLX14, a Denosumab Biosimilar
- Big Molecule WatchNovember 7, 2024
Daewoong and Celltrion to Market Denosumab Biosimilar in Korea
- Big Molecule WatchNovember 6, 2024
EMA Accepts Marketing Authorization Application for Alvotech’s AVT05 (golimumab)
- Big Molecule WatchNovember 5, 2024
Alvotech Requests that FDA Refuse to License CHO-Cell Derived Ustekinumab Biosimilars as Interchangeable Until the Effects of Sialylation Are Evaluated
- Big Molecule WatchNovember 5, 2024
Amgen Launches Its Aflibercept Biosimilar In the U.S.
- Life Sciences PerspectivesNovember 4, 2024
New Momentum for a Time-Limited Conditional Approval Pathway for Rare Disease Drugs
- InsightNovember 4, 2024
New Momentum for a Time-Limited Conditional Approval Pathway for Rare Disease Drugs
- Speaking EngagementsNovember 12, 2024
US & EP Data Exclusivity: Same Name, Different Games
- Press ReleaseNovember 8, 2024
AlloVir and Kalaris Therapeutics to Merge
- Press ReleaseNovember 7, 2024
Goodwin Advises Anika on Strategic Update of Business with Sale of Arthrosurface
- Awards and RankingsNovember 7, 2024
Best Lawyers Best Law Firms 2025 Names Goodwin Biotechnology and Life Sciences Law Firm of the Year for the Eighth Time and Recognizes 55 Practice Areas
- In the PressNovember 5, 2024
The Guide to Life Sciences: FTC Pharma Scrutiny Expected to Continue Following Step Up in Killer Acquisition Enforcement (GCR)
- Press Release4 November 2024
Scalpel AI Raises £3.8 Million in Funding
- Press ReleaseNovember 4, 2024
Goodwin Advises Axonis Therapeutics in $115 Million Series A Financing
- Press ReleaseNovember 1, 2024
Goodwin Advises ProQR on $69.8 Million Underwritten Public Offering Closing and $12.3 Million Concurrent Private Placement